Another Feather In Cap For Orchard’s Gene Therapy Product Following UK PIM designation

Orchard Therapeutics’ gene therapy product for treating the rare, so called “bubble baby” disease has been granted a “promising innovative medicine” designation under the UK’s early access to medicine scheme. The product already has orphan drug, breakthrough therapy and rare pediatric disease designations in the US.